Metotrexato Semanal Wyeth

Methotrexate, the active ingredient in Metotrexato Semanal Wyeth, is an antimetabolite presented as an oral formulation for oral use. It is employed as an immunosuppressant to manage inflammatory and autoimmune conditions such as rheumatoid arthritis, psoriasis and juvenile idiopathic arthritis.

GNH USA supplies Metotrexato Semanal Wyeth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts as an antimetabolite that modulates immune activity in several chronic inflammatory diseases. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin plaque formation and severity. - Juvenile idiopathic arthritis: controls systemic inflammation and improves joint function.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: mild to moderate gastrointestinal upset. - Fatigue: persistent tiredness unrelated to activity level. - Oral ulceration: sores or inflammation in the mouth. - Elevated liver enzymes: mild hepatic irritation detectable on labs. - Hair thinning: temporary reduction in hair density. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis. - Bone marrow suppression: leading to anemia, leukopenia or thrombocytopenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe infection: opportunistic infections due to immunosuppression. - Renal impairment: decreased clearance causing toxicity. - Rare hypersensitivity reactions: including Stevens‑Johnson syndrome.

Methotrexate requires careful monitoring and specific safety measures. - Liver monitoring: perform baseline and periodic liver function tests. - Hematologic monitoring: check complete blood counts regularly. - Renal function: assess creatinine clearance before and during therapy. - Pregnancy contraindication: avoid use in pregnancy due to teratogenicity (Category X). - Contraception: both males and females should use effective contraception during treatment. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Methotrexate interacts with several drug classes that may alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate plasma levels and risk of toxicity. - Proton pump inhibitors: may reduce renal clearance, raising systemic exposure. - Sulfonamide antibiotics: potentiate bone marrow suppression.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: may enhance hematologic toxicity. - Oral contraceptives: may reduce methotrexate effectiveness. - Live vaccines: increased risk of infection; avoid concurrent administration.